| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.2 | 0.5 |
| Net income | -82.1 | -3.7 |
| EPS (diluted, $ a share) | $-4.52 | $-1.29 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +342.4% |
|---|
10-Q filed with the SEC, NASDAQ: ENSC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ensysce Biosciences, Inc.: key numbers
- Share price
- $0.4095Close, Nov 16
- Market cap
- $7.97M
- Shares outstanding
- 19.46MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ensysce Biosciences, Inc.
All →Ensysce Biosciences Financial Results
Ensysce Biosciences reported financial results for the third quarter of 2026, highlighting the completion of its acquisition of Cy Biopharma and the addition of lead asset CY200 for Complex Regional Pain Syndrome. The company ended the quarter with a strengthened cash position of $29.7 million and submitted a Phase 2a protocol for CY200 to the UK's MHRA.
- Term
- Q3 2026
“Ensysce is a fundamentally different company today than it was at the start of the year. With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”
Dr. Lynn Kirkpatrick, Chief Executive Officer
“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step.”
James Morrison, President of Ensysce
Ensysce Biosciences Leadership Change
Ensysce Biosciences announced a leadership transition where current CEO Dr. Lynn Kirkpatrick will step down and assume the role of Chief Operating Officer following the annual meeting on December 14, 2026. Current President James Morrisson will succeed her as Chief Executive Officer. Additionally, board member Will Chang notified the company of his intention to resign following the same annual meeting.
Ensysce Biosciences M&A Deal with Cy Biopharma, Inc.
Ensysce Biosciences completed the acquisition of Cy Biopharma, Inc. on August 5, 2026, through a two-step merger process. As consideration, Ensysce issued 282,122 shares of Series C Preferred Stock to Cy Biopharma equityholders, with each share convertible into 1,000 shares of common stock. This filing (Amendment No. 2) provides required historical and pro forma financial statements related to the transaction.
- Counterparty
- Cy Biopharma, Inc.
Ensysce Biosciences Other 8-K Filing
Ensysce Biosciences filed an amendment to its Series C Non-Voting Convertible Preferred Stock certificate of designation to remove a cash redemption option. Previously, Section 6.5.3 allowed holders to redeem shares for cash if the company failed to deliver common stock upon conversion; this provision has now been eliminated.